

New release of QuickNavi™-Noro 3, a Rapid Antigen Test for Norovirus, on October 26 in Japan — Higher Sensitivity to Various Genotypes —



QuickNavi™-Noro 3, Rapid Antigen Test for Norovirus

Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Toshio Imai; hereinafter, “Denka”) will introduce QuickNavi™-Noro 3, a rapid antigen test for norovirus, on October 26 to medical facilities in Japan.¹ QuickNavi™ products are *In Vitro* Diagnostics product and this new QuickNavi™ product is more sensitive to various genotypes of norovirus than the conventional version already available in market from Denka.

Norovirus is known to be the main cause of infectious gastroenteritis. Infectious gastroenteritis may occur when norovirus enters the body from the mouth via food, hands and other fomites or if viral particles in the air are inhaled. Infections are found mainly in winter although found throughout the year. The risk of outbreak is present in schools, elderly nursing homes and other types of group homes. Norovirus has many different genotypes which differ from one another in their antigenicity. Thus, presumably many people have no immunity to the virus and the prevalence of norovirus is expected to continue in the future.² The ability to accurately detect antigens regardless of different norovirus genotypes is clinically significant, just as it is for antigens of SARS-CoV-2 variants.

QuickNavi™-Noro 3 determines if any norovirus antigens are present in stool using immunochromatography. If antigens are present, it can rapidly detect within 15 minutes after addition of a sample to the test device. The new product is more sensitive to many genotypes than its conventional one from Denka, QuickNavi™-Noro 2. New product will be sold by Denka, as well as Otsuka Pharmaceutical Co., Ltd. (headquarters: Chiyoda-ku, Tokyo; President and Representative Director: Makoto Inoue).

QuickNavi™ products are rapid antigen tests and available for the detection of various antigens such as SARS-CoV-2, influenza viruses, adenovirus, respiratory syncytial virus, *Mycoplasma pneumoniae*, *Helicobacter pylori* and more. We will continue to produce and supply rapid antigen tests flexibly responding to the number of infectious disease cases and market demand.

Having positioned healthcare as a priority field, Denka considers that it is our responsibility to the society to take measures to prevent infectious diseases. As the only company in Japan which manufactures and sells rapid antigen tests as well as influenza vaccines, Denka is working to prevent the spread of infectious diseases from aspects of both prevention and diagnosis. With the SDGs as its compass, Denka aims to be an irreplaceable company for society, creating a better world for all through the work Denka is specialized in.

¹The product is only for *In Vitro* diagnostic use and limited to medical facilities. It is not commercially available to general public.

²Q&A on norovirus, Ministry of Health, Labour and Welfare *Japanese

https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryuu/shokuhin/syokuchu/kanren/yobou/040204-1.html

*Please also refer to our website, which provides general information on norovirus.

Denka's Medical Q&A: Norovirus https://denka-medical.info/qa_noro/ *Japanese

QuickNavi™-Noro 3 Quick Procedure Guide and Example of Results *Japanese

Product Overview

Product Name	QuickNavi™-Noro 3 (product number: 326300)
Target	Norovirus antigen
Specimen	Stool
Reaction Time	Up to 15 minutes after addition of specimen
Storage	2 to 30°C
Shelf Life	24 months from the date of manufacturing
Packaging	10 tests /pack
Suggested Retail Price	15,000 yen (excluding tax)

[For Inquiries from Media]
 Corporate Communications Dept. Tel: +81-3-5290-5511
 [For Inquiries from Medical Institutions]
 Domestic Reagents Dept. of Vaccines and Diagnostics Business Headquarters, Life Innovation
 Tel: +81-3-6214-3235